Premium
Interleukin 4 inhibits the proliferation and promotes the maturation of human leukemic early B cells
Author(s) -
Ouaaz Fateh,
Mentz Franz,
Mossalayi M. Djavad,
Schmitt Christian,
Michel Ariane,
Debre Patrice,
Guillosson JeanJaques,
MerleBeral Hélène,
Arock Michel
Publication year - 1993
Publication title -
european journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0902-4441
DOI - 10.1111/j.1600-0609.1993.tb01608.x
Subject(s) - monoclonal antibody , cytokine , microbiology and biotechnology , cell culture , cell growth , leukemia , recombinant dna , in vitro , biology , chemistry , interleukin 4 , antibody , cancer research , immunology , gene , biochemistry , genetics
The effects of interleukin 4 (IL‐4) on human leukemic precursor B‐cell lines were investigated. Recombinant IL‐4 (rIL‐4) was added to three acute lymphoblastic leukemia‐derived pre B‐cell lines: Reh, Km3 and Nalm‐6. Our results show that rIL‐4 significantly decreases continuous proliferation of Reh and Km3 cells while Nalm‐6 cells have a limited response in this respect. This rIL‐4 effect is dose‐dependent and can be neutralized by anti‐IL‐4 monoclonal antibody (mAb). Furthermore, rIL‐4 down‐regulated IL‐3‐induced proliferation of Reh cells. Phenotypic analysis of rIL‐4‐treated cells points to significant induction of surface marker maturation of leukemic cells by this cytokine. Together, these in vitro data suggest that IL‐4: 1) inhibits the proliferation and 2) promotes the differentiation of certain human leukemic B‐cell precursors.